Although drugs that directly target the U2AF1 mutation are currently lacking, splicing modulators targeting the U2AF1 mutation have shown potential therapeutic efficacy in U2AF1 mutated myeloid malignancies, raising the possibility of applying splicing modulators to patients harboring U2AF1 mutations. The gene discussed is U2AF1; the disease is myeloid neoplasm.